... The Government has promised a £200million cancer drug fund to pay for any medicine recommended by a consultant - even when it has not been licensed to treat a specific disease.
But the initiative will not come into force until next April, leaving patients at the mercy of NICE for nine more months.
...
The Rarer Cancers Foundation said it was a scandal that so many patients will see their lives cut short when there are drugs available - and widely used in Europe and the U.S. - which could give them precious extra months.
...
The drugs which have been turned down provisionally are: sorafenib for liver cancer; lapatinib and bevacizumab for breast cancer; trabectedin for ovarian cancer; erlotinib for lung cancer; ofatumumab for leukaemia; imatinib for intestinal tumours; everolimus for kidney cancer; trastuzumab for gastric cancer and mifamurtide for bone cancer
...
DESPUES DE 18 AÑOS CON SOLO TOPOTECAN CON FULL APPROVAL EN EEUU COMO TREATMENT 2a LÍNE SCLC-ES ... LA USFDA ACABA DE APROBAR AL TARLATAMAB CON FULL APPROVAL ... POR LO QUE ES YA EL NEW TREATMENT STÁNDARD EN EEUU . TIENE APROBACIÓNES ACELERADAS EN CANADA , UK, COREA ... Y EN DÍAS PODRÍA ALCANZAR LA APROBACIÓN TAMBIÉN EN CHINA QUE EN JULIO 2025, LA NMPA ACEPTÓ LA SOLICITUD DE REGISTRO (NDA) PARA TARLA OTORGÁNDOLE ADEMAS LA REVISIÓN PRIORITARIA . LA EMA TAMBIÉN LO ESTÁ YA EVALUANDO .